Loading clinical trials...
Loading clinical trials...
To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) vers...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT05870969 · Carcinoma, Hepatocellular, Hepatitis C, Chronic, and more
NCT03200379 · Hepatitis C, Chronic
NCT03155906 · Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy
NCT03987503 · Hepatitis C, Chronic
NCT05397067 · Hepatitis C, Chronic, Substance Use Disorders
1241.30.10003 Boehringer Ingelheim Investigational Site
La Mesa, California
1241.30.10007 Boehringer Ingelheim Investigational Site
San Diego, California
1241.30.10001 Boehringer Ingelheim Investigational Site
DeLand, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions